You searched for "cancer"
The eye surgeon and eye physician together: the joint ophthalmic clinic
Since the early 19th century, physicians and surgeons have been working together in eye clinics and hospitals to bring about the best outcome for the patients. From the early Babylonian age, important advances in ophthalmic knowledge arose in a stuttered...Inverness resident leads the way with sight loss walking group
An Inverness resident, supported by a national sight loss charity, meets monthly with other blind and partially sighted locals for a wander around Inverness city centre.
Licence to save: a UK survey of anti-VEGF use for the eye
This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...Nominations open for AOP elected and designated Council positions
The Association of Optometrists invites nominations from eligible members for its 2024 Council elections.Does beauty truly lie in the eye of the beholder?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Does beauty truly lie in the eye of the beholder? Scleral whitening, iris colour-changing drops and...Will COVID-19 impact the selection of ophthalmology as a career choice by medical students?
The COVID-19 pandemic has had profound effects on medical education and has called for large shifts in the medical curriculum. Clinical attachments were suspended at the height of the pandemic and examinations were cancelled or were moved to an online...
Intravitreal Ziv-Aflibercept: safety analysis
Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...
Exploring the potential of neurodegenerative disease screening within age-related eye disease research
The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...
